Osimertinib granted accelerated FDA approval for lung cancer treatment
Osimertinib, a product of AstraZeneca Pharmaceuticals LP, can be used to treat patients who have had a positive, FDA-approved test for metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
Additionally, patients must have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy in order to qualify for the treatment.
Organizations in this story
U.S. Food and Drug Administration (FDA) 10903 New Hampshire Ave Silver Spring, MD 20903
AstraZeneca Pharmaceuticals LP 1800 Concord Pike Wilmington, DE 19803